Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1
There is significant interpatient variability in the plasma concentration of lenalidomide. Studies have found that the pharmacokinetic (PK) parameters of lenalidomide may be correlated with its toxicity. Therefore, it is important to develop population pharmacokinetic (PPK) studies on lenalidomide to identify factors contributing to interpatient PK differences. Current lenalidomide PPK studies have all examined conventional factors such as demographic characteristics, laboratory test results and so on, yet hardly any of them has examined genetic polymorphism. We utilize a nonlinear mixed-effects model (NONMEM) to conduct a PPK study on lenalidomide in Chinese patients incorporating the genotypes of ABCB1 3435 C>T (rs1045642), ABCB1 1236 A>G (rs1128503) and ABCB1 2677 A>C/T (rs2032582) which have higher mutation frequencies in the Chinese population, in the hope of exploring factors associated with the adverse events (AEs) of lenalidomide from a PK perspective.